Muñoz Laura, Stagg Helen R, Abubakar Ibrahim
Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, Barcelona 08970, Spain Research Department of Infection and Population Health, University College London, London WC1E 6JB, United Kingdom.
Research Department of Infection and Population Health, University College London, London WC1E 6JB, United Kingdom.
Cold Spring Harb Perspect Med. 2015 Jun 8;5(11):a017830. doi: 10.1101/cshperspect.a017830.
The post-2015 World Health Organization global tuberculosis strategy recognizes that elimination requires a focus on reducing the pool of latently infected individuals, an estimated 30% of the global population, from which future tuberculosis cases would be generated. Tackling latent tuberculosis infection requires the identification and treatment of asymptomatic individuals to reduce the risk of progression to active disease. Diagnosis of latent tuberculosis infection is based on the detection of an immune response to Mycobacterium tuberculosis antigens using either the tuberculin skin test or interferon-γ release assays. Current treatment requires the use of antibiotics for at least 3 months. In this article, we review the current knowledge of the natural history, immunology, and pathogenesis of latent tuberculosis, describe key population groups for screening and risk assessment, discuss clinical management in terms of diagnosis and preventative treatment, and identify areas for future research.
2015年后世界卫生组织全球结核病战略认识到,要实现结核病消除目标,需要重点关注减少潜伏感染人群数量,这部分人群估计占全球人口的30%,未来的结核病病例将由此产生。应对潜伏性结核感染需要识别并治疗无症状个体,以降低发展为活动性疾病的风险。潜伏性结核感染的诊断基于使用结核菌素皮肤试验或干扰素-γ释放试验检测对结核分枝杆菌抗原的免疫反应。目前的治疗需要使用抗生素至少3个月。在本文中,我们综述了潜伏性结核的自然史、免疫学和发病机制的现有知识,描述了筛查和风险评估的关键人群组,讨论了诊断和预防性治疗方面的临床管理,并确定了未来研究的领域。